US FDA warns King on misleading claims in Embeda news releases
This article was originally published in Scrip
The US FDA has warned King Pharmaceuticals that video news releases announcing approval of the company's long-acting opioid Embeda extended-release (morphine sulphate plus naltrexone hydrochloride) are false, misleading and "grossly" minimise the drug's potential serious risks.
You may also be interested in...
Amivas requested a US tropical disease PRV for intravenous artesunate but FDA has not yet made a decision on eligibility; approval appears to block La Jolla’s competing product, currently under review, for seven years.
Providing information in a pre-IND meeting request will facilitate a more efficient development process, agency says in a new guidance; generally, there is insufficient information to assess if and when an emergency use authorization might be appropriate when a sponsor first enters discussions with the FDA.
CDER wants sponsors to use the NextGen Portal for electronic submission of promotional pieces to the Office of Prescription Drug Promotion, rather than sending in paper or physical media such as CDs; availability of this alternative pathway does not affect requirement for eCTD submission of some types of promotional materials starting in June 2021.